ClinicalTrials.gg

Chagas Disease clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 73 studies for Chagas Disease across more than 10 countries. 5 are recruiting or about to start. 54 of them are mainly about Chagas Disease (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its narrower condition Chagas Cardiomyopathy too: 80 studies, 6 open.

Status

Completed
50
Status unknown
13
Recruiting
3
Terminated
2
Not yet recruiting
2
Active, not recruiting
2

Phase

Phase 2
15
Phase 3
13
Phase 1
8
Phase 4
8
Early Phase 1
1

Where

Brazil
28
Argentina
26
Bolivia
10
Colombia
10
United States
7
Spain
7

Who develops what

Add Chagas Disease to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 2 programs from 2 companies, 2 with this as their studies’ main aim; 0 with a live phase 3 study; 1 primary completion in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
benzonidazoleRecent, limited
Evidence
  • NCT06632600 · Novartis · Phase 2 · live · comparator · “Benznidazole” · registered Oct 2024
  • NCT04897516 · Laboratorio Elea Phoenix S.A. · Phase 3 · live · standard-care · “Standard treatment with benznidazole” · registered May 2021
Insud Pharma50% of its industry studiesUS: Chemo Research (FDA 2017)11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 2 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 22 Jul 2027 est.LXE408 · Novartis · Phase 2 main aimvs benzonidazoleNCT06632600 A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease. — primary endpoint: Presence or absence of sustained parasitological clearance using polymerase chain reaction (PCR) results over 6 months - LXE408 28 days versus placebo. · 130 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Chagas Disease studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

2studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 2, phase 3 first

Who these studies take

Of the 3 Chagas Disease studies recruiting now, 1 (33%) set no upper age limit and 2 (67%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 3
AgeWomenMen
100 (0%)0 (0%)
183 (100%)3 (100%)
303 (100%)3 (100%)
403 (100%)3 (100%)
503 (100%)3 (100%)
651 (33%)1 (33%)
751 (33%)1 (33%)
851 (33%)1 (33%)

Across all 73 studies, recruiting or not: 67% stop at 75 or younger and 51% at 65; 16% take children; 7% are for women only and 3% for men only; 19% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 50 of 73. Browse all 73 → or search them.